Fortress Biotech, Inc.
FBIO
$1.68
$0.042.44%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 24.14% | 38.05% | 57.51% | 40.97% | 29.96% |
| Total Depreciation and Amortization | -25.56% | -33.90% | -36.22% | -37.71% | -18.81% |
| Total Amortization of Deferred Charges | -32.26% | -26.77% | -15.27% | 29.18% | 46.83% |
| Total Other Non-Cash Items | 49.16% | 49.69% | 57.09% | 51.53% | 36.89% |
| Change in Net Operating Assets | 35.08% | -409.12% | -263.51% | -217.24% | -1,650.91% |
| Cash from Operations | 37.46% | 27.57% | 40.98% | 37.19% | 28.53% |
| Capital Expenditure | -- | 77.78% | 97.38% | 95.43% | 97.68% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | 4,624.41% | 4,624.41% | 4,624.41% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -86.57% | 99.58% | 85.91% | 43.07% | 60.47% |
| Cash from Investing | -613.27% | 97.41% | 159.31% | 143.95% | 90.83% |
| Total Debt Issued | 2.68% | 61.20% | -48.61% | -61.75% | -18.39% |
| Total Debt Repaid | 98.48% | 99.38% | 85.73% | -64.77% | -946.83% |
| Issuance of Common Stock | -1.21% | 103.96% | 68.24% | 64.74% | 268.88% |
| Repurchase of Common Stock | -- | -37,800.00% | -37,800.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -370.59% | -370.59% | -370.59% | -370.59% |
| Total Dividends Paid | 50.00% | 24.99% | -0.01% | -0.01% | -0.01% |
| Other Financing Activities | -82.17% | -78.59% | 30.52% | 74.03% | 64.38% |
| Cash from Financing | 115.77% | 1,042.95% | 486.15% | -19.21% | -56.53% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 74.84% | 89.82% | 93.23% | 48.75% | 23.16% |